Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx abuse monitoring law

Executive Summary

President Bush signs the "National All Schedules Prescription Electronic Reporting Act" into law Aug. 11. The law, which passed the House July 27 and the Senate July 29, authorizes $60 mil. over fiscal years 2006-2010 for states to create or augment monitoring systems to track prescriptions of Schedule II-IV drugs across state lines (1"The Pink Sheet" Aug. 8, 2005, p. 27). The monitoring programs will require healthcare providers to report the dispensation of controlled substances within a week. Following a public comment period, the Secretary of HHS will establish minimum requirements, including certain privacy provisions, that states must meet in order to be eligible for grants under the law...

You may also be interested in...



Importation Limits In Future Trade Agreements Prevented Under Vitter Bill

Pharmaceutical importation prohibitions in future U.S. trade agreements would be forbidden under a bill co-sponsored by Sens. David Vitter (R-La.) and Debbie Stabenow (D-Mich.)

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel